Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who test positive for the hepatitis B surface antigen (a marker showing hepatitis B is present in the body)
- People whose liver enzyme levels (ALT) have stayed within the normal range over two separate tests, taken 3 to 6 months apart — normal is below 30 IU/ml for males and below 20 IU/ml for females
- People whose hepatitis B virus levels in the blood are below 2,000 IU/ml
- People whose liver stiffness measurement (a scan that checks for liver scarring) is below 8 kPa
Who may not be able to join:
- People who have previously been treated with antiviral medications (NUCs) or interferon therapy for hepatitis B
- People with reduced kidney function, indicated by a blood creatinine level above 1.5 mg/dl
- People who have been diagnosed with liver cirrhosis (severe liver scarring) or enlarged veins in the food pipe (esophageal varices)
- People who have experienced serious complications from liver disease (confirm with trial site)
- People who already have liver cancer (hepatocellular carcinoma)
- People who are pregnant
- People who work in healthcare
- People who have had an organ transplant, have an advanced cancer diagnosis, or are currently receiving chemotherapy
- People who also have hepatitis C, hepatitis D, or HIV
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 01146300000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients with HBV DNA <2000 IU/ml, normal ALT and no significant fibrosis (as per APASL 2015).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.